-The Times of India NEW DELHI: If the dictum 'you can't manage what you can't measure' is true, then the government has an unsure grip over at least half the 13 flagship schemes worth nearly Rs 2 lakh crore annually, almost 80% of the total spend on central schemes. The government is unable to efficiently collate information to assess whether some of the 13 key flagship schemes are producing the results for...

-The Business Standard USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly The following two quotes from the United States Food and Drug Administration (FDA) news releases may help put the Ranbaxy controversy in perspective. The first sums up what it is that drives the FDA and the second is typical of the challenge the pharmaceutical industry faces. (1) "The consent...

Argumentative Indians are at it again! After sparring over the poverty line and the actual number of poor, India's renowned economists have fired up a fresh debate over the extent of malnutrition. In the earlier debate, the Planning Commission ‘reduced' poverty on paper disregarding NSSO and official committees, including the NCEUS, which determined that 77% Indians survived on less than Rs 20 a day. Columbia university economist Arvind Panagariya has...

-The United Nations A United Nations report released today stresses the importance of providing meals for schoolchildren, particularly in times of crisis, and notes that this is still lacking in many developing countries. "School feeding assures that where quality education is available, children are able to take advantage of the opportunity to learn," said the Executive Director of the World Food Programme (WFP), Ertharin Cousin. "It's an investment that pays off in the...

-The Hindu   Ranbaxy's fraudulent practices may have jeopardised millions of lives in India, Africa and the U.S. Exactly two weeks ago, the pharmaceuticals industry was rocked by revelations that one of the world's largest generic drug manufacturers, Ranbaxy Laboratories, pleaded guilty to seven federal criminal charges stemming from its fraudulent production practices dating back to 2008, and agreed to pay U.S. regulators $500 million in fines. Much has since been said about Ranbaxy's...